Centene (CNC) Stock Forecast & Price Target

Centene is supported by its scale and diversification across Medicaid, Medicare, Medicare Part D, and the individual exchanges, with about 20 million medical members and leading Medicaid exposure that creates strong barriers to entry. The bullish case is reinforced by higher FY26 guidance and rising adjusted EPS estimates, alongside improving health benefit ratio trends as Medicaid cost pressure stabilizes, Marketplace margins recover after 100% repricing, and Medicare Advantage moves toward breakeven. Management’s constructive rate dialogue, multi-state contract wins, and D-SNP alignment opportunity also provide durable revenue visibility and longer-term margin expansion potential.

Centene is burdened by heavy government-program exposure, with Medicaid representing about 64% of 20 million medical members and facing OBBBA-driven federal funding cuts, work requirements, more frequent redeterminations, and state budget pressure that could keep rate increases below medical trend. The company’s 2025 results already show the strain, including a roughly -1% pre-tax margin versus a 5% to 7.5% target range, a $6.7 billion goodwill impairment in 3Q25, and membership pressure from acuity shifts, elevated behavioral health and drug costs, and a 2025 Medicaid HBR that ran above normal levels. In addition, Marketplace risk adjustment uncertainty, PDP margin compression from above 3% in 2025 to about 2% in 2026, and Medicare utilization around 92% collectively signal persistent earnings volatility and limited visibility into a clean margin recovery.